阿瑞匹坦联合奥美拉唑对肺癌化疗患者的止吐效果  

Antiemetic efficacy of aripiprazole combined with omeprazole in patients with lung cancer receiving chemotherapy

作　　者：梁丹 宋央央 王剑 Liang Dan;Song Yang-yang;Wang Jian(Department of Oncology,Shangyu People’s Hospital,Shaoxing 312300,China;Department of Oncology,Xinchang County Hospital of Traditional Chinese Medicine,Shaoxing 312500,China)

机构地区：[1]绍兴市上虞人民医院肿瘤内科,绍兴312300 [2]新昌县中医院肿瘤内科,绍兴312500

出　　处：《中国药物应用与监测》2025年第1期170-173,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的探究阿瑞匹坦联合奥美拉唑对肺癌化疗患者的止吐效果。方法回顾性分析2021年6月至2024年6月绍兴市上虞人民医院肿瘤科与新昌县中医院肿瘤科进行化疗的非小细胞肺癌患者90例,根据止吐治疗方案的不同分为对照组(43例,阿瑞匹坦、地塞米松、昂丹司琼)和观察组(47例,奥美拉唑、阿瑞匹坦、地塞米松、昂丹司琼)。对比两组患者治疗后恶心和呕吐完全缓解率、功能性生活指数量表评分及不良反应发生情况。结果观察组全程期、延迟期的恶心、呕吐完全缓解率分别为83.72%(36/43)、86.05%(37/43)均高于对照组62.50%(25/40)、67.50%(27/40)(χ^(2)=4.791、4.038,均P<0.05);观察组、对照组急性期的恶心、呕吐完全缓解率分别为88.37%(38/43)、85.00%(34/40),两组比较差异无统计学意义(χ^(2)=0.205,P=0.651)。化疗3、5 d后,观察组的功能性生活指数量表、恶心子量表评分[分别为(44.33±3.67)分、(47.54±5.23)分]均高于对照组[(40.77±3.82)分、(43.68±4.95)分](t=4.508、3.588,均P<0.05);观察组的呕吐子量表评分[分别为(45.51±3.93)分、(50.35±5.67)分]均高于对照组[分别为(41.82±3.99)分、(44.75±5.15)分](t=4.417、4.889,均P<0.05)。两组头晕、乏力、便秘、呃逆比较差异无统计学意义(P>0.05)。观察组胃肠功能紊乱、食欲减退的发生率分别为29.79%(14/47)、25.53%(12/47),均高于对照组的11.63%(5/43)、9.30%(4/43)(χ^(2)=4.446、4.046,均P<0.05)。结论阿瑞匹坦联合奥美拉唑可以更好地缓解肺癌化疗患者的恶心、呕吐,但需监测奥美拉唑药物浓度,以减少不良反应的发生。Objective To explore the antiemetic efficacy of aripiprazole combined with omeprazole in patients with lung cancer undergoing chemotherapy.Methods A retrospective analysis was conducted on 90 non-small cell lung cancer patients undergoing chemotherapy in the Department of Oncology of Shangyu People’s Hospital and the Department of Oncology of Xinchang County Hospital of Traditional Chinese Medicine from June 2021 to June 2024.According to the different antiemetic treatment plans,43 cases were included in the control group(aripiprazole,dexamethasone,ondansetron)and other 47 were included in the observation group(omeprazole,aripiprazole,dexamethasone,ondansetron).The complete remission rate of nausea and vomiting,functional living index-emesis(FLIE)scores and adverse reaction occurrence were compared between the two groups after treatment.Results The complete remission rates of nausea and vomiting duration,the entire course and the delay phase in the observation group were 83.72%(36/43)and 86.05%(37/43),respectively,which were higher than those of 62.50%(25/40)and 67.50%(27/40)in the control(χ^(2)=4.791,4.038,both P<0.05).The complete remission rates of nausea and vomiting in the acute phase for the observation group and the control group were 88.37%(38/43)and 85.00%(34/40),respectively,showing no statistically significant difference between the two groups(χ^(2)=0.205,P=0.651).The FLIE nausea subscale scores on day 3 and day 5 after chemotherapy in the observation group were(44.33±3.67)and(47.54±5.23),respectively,both of which were higher than those of(40.77±3.82)and(43.68±4.95)in the control(t=4.508,3.588,both P<0.05).The FLIE vomiting subscale scores in the observation group were(45.51±3.93)and(50.35±5.67),respectively,both of which were higher than those of(41.82±3.99)and(44.75±5.15)in the control(t=4.417,4.889,both P<0.05).There was no statistically significant difference in the incidence of dizziness,fatigue,constipation and hiccups between the two groups(P>0.05).The incidence of gastrointestinal

关 键 词：阿瑞匹坦 奥美拉唑 肺癌 化疗 恶心 呕吐 安全性 

分 类 号：R734.2[医药卫生—肿瘤]